Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CYB003 in Major Depressive Disorder and Anxiety
NCT06820723Phase 2Recruiting
- Sponsor
- The Ohio State University
- Start
- Nov 2026
- Primary completion
- Nov 2028
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in major depressive disorder (MDD) and anxiety disorder comparing CYB003 with Placebo (2 arms). Primary endpoints: Changes in parameter estimate of regional brain activity measured by fMRI at 21 days, Changes in region-to-region connectivity measured by fMRI at 21 days and 2 more. Started Nov 2026; status: recruiting.
02
Drugs
CYB003
03
Conditions
major depressive disorder (MDD)anxiety disorder
Beyond the preview
Go deeper on NCT06820723.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06820723.